Michelin: Lancement du nouveau plan mondial d’actionnariat salarié : BIB’Action 2024
September 10, 2024 02:25 ET
|
Michelin
Clermont-Ferrand, le 10 septembre 2024 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Engagement et partage de la valeur : lancement du nouveau plan mondial d’actionnariat salarié «...
Michelin launches a new global employee share ownership plan: BIB'Action 2024
September 10, 2024 02:25 ET
|
Michelin
Clermont-Ferrand – September 10, 2024 COMPAGNIE GÉNÉRALE DES ÉTABLISSEMENTS MICHELIN Commitment and value sharing: Michelin launches a new global employee share ownership plan “BIB’Action...
Progress on share buyback programme
September 10, 2024 02:00 ET
|
ING Group
Progress on share buyback programme ING announced today that, as part of our €2.5 billion share buyback programme announced on 2 May 2024, the company repurchased 3,625,795 shares during the week of...
Orapi : Resultats du Premier Semestre 2024
September 10, 2024 02:00 ET
|
ORAPI
Communiqué de presse Lyon – Saint-Vulbas, le 10 septembre 2024 à 8h00 Stabilité de l’EBITDA du S1 2024 vs 2023 ROC* S1 2024 : 1,5% du CA Résultat net à -13,7M€ vs -5,8 M€ en 2023 En M€S1...
Correction: Signaux Girod : Déclaration rachat actions propres semaine 36/2024
September 10, 2024 01:51 ET
|
Signaux Girod
SIGNAUX GIROD Société anonyme au capital de 13 422 500 € Siège social : 881, route des fontaines 39400 BELLEFONTAINE 646 050 476 R.C.S. LONS-LE-SAUNIER Code ISIN : FR0000060790 DECLARATION ...
BGHL (EUR): NAV(s)
September 10, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (EUR)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
BGHL (GBP): NAV(s)
September 10, 2024 01:30 ET
|
BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)
BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following...
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à petites cellules
September 10, 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics annonce le lancement international d’Artemia, l’étude de Phase 3 d’enregistrement du vaccin thérapeutique Tedopi® en deuxième ligne de traitement du cancer du poumon non à...
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer
September 10, 2024 01:30 ET
|
OSE Immunotherapeutics
OSE Immunotherapeutics Announces Global Launch of Artemia Phase 3 Registration Study for Cancer Vaccine Tedopi® in Second-Line Non-Small Cell Lung Cancer Trial begins in the United States, Canada,...
Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report
September 09, 2024 15:45 ET
|
Planisware
Planisware recognized as a Leader in 2024 Gartner® Magic Quadrant™ for Adaptive Project Management & Reporting report Paris, France, September 9, 2024 – Planisware, a leading B2B provider of...